Article info
PDFLaw, ethics and medicine
Paper
Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I
- Correspondence to Professor Ida Vanessa Schwartz, Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos, 2350, CEP 90035-003, Porto Alegre, RS, Brazil; ischwartz{at}hcpa.ufrgs.br
Citation
Ethical issues related to the access to orphan drugs in Brazil: the case of mucopolysaccharidosis type I
Publication history
- Received April 6, 2010
- Revised September 14, 2010
- Accepted October 4, 2010
- First published January 25, 2011.
Online issue publication
March 17, 2011
Article Versions
- Previous version (25 January 2011).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Other content recommended for you
- Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I
- Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis
- Mucopolysaccharidosis type I disguised as rickets
- Commissioning for rare diseases: view from the frontline
- Should rare diseases get special treatment?
- Clinical course of sly syndrome (mucopolysaccharidosis type VII)
- ‘Doctor Google’ ending the diagnostic odyssey in lysosomal storage disorders: parents using internet search engines as an efficient diagnostic strategy in rare diseases
- Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres
- Orphan drugs and the NHS: should we value rarity?
- AB0137 Characterization of joint disease in mucopolysaccharidosis type I mice and the effects of enzyme replacement therapy